India, May 17 -- Nanobiotix (NBTX) announced the presentation of Part 1 data from the Johnson & Johnson-sponsored CONVERGE study, a randomized Phase 2 clinical trial evaluating the potential first-in-class Nanoradioenhancer JNJ-1900 (NBTXR3) for patients with stage III inoperable non-small cell lung cancer (NSCLC), at the 2026 European Society for Radiotherapy and Oncology Annual Meeting.
Early findings indicated that intratumoral and intranodal injection of JNJ-1900 (NBTXR3) is both feasible and safe for patients with stage III unresectable NSCLC. Importantly, initial efficacy responses observed in seven patients who completed the full treatment regimen-which included concurrent chemoradiotherapy, JNJ-1900 (NBTXR3), and consolidation with...